MS
MCID: MLT020
MIFTS: 81

Multiple Sclerosis (MS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Multiple Sclerosis

MalaCards integrated aliases for Multiple Sclerosis:

Name: Multiple Sclerosis 57 11 19 42 52 75 73 53 5 41 43 14 36 71 31 33
Ms 57 19 42 73
Multiple Sclerosis, Susceptibility to 57 28 5
Disseminated Sclerosis 57 42 33
Multiple Sclerosis, Disease Progression, Modifier of 57 12
Multiple Sclerosis Modifier of Disease Progression 28 5
Multiple Sclerosis, Susceptibility to 1 28 5
Insular Sclerosis 11 33
Disseminated Nervous System Myelosclerosis 33
Multiple Combined Sclerosis of Spinal Cord 33
Multiple Sclerosis, Susceptibility to, 1 57
Multiple Sclerosis of the Spinal Cord 33
Multiple Sclerosis Susceptibility to 38
Disseminated Cerebrospinal Sclerosis 33
Multiple Sclerosis of the Brain Stem 33
Multiple Cerebrospinal Sclerosis 33
Multiple Sclerosis of Brain Stem 33
Disseminated Multiple Sclerosis 33
Generalized Multiple Sclerosis 11
Generalised Multiple Sclerosis 33
Multiple Sclerosis Generalised 33
Disseminated Spinal Sclerosis 33
Disseminated Brain Sclerosis 33
Multiple Ascending Sclerosis 33
Multiple Combined Sclerosis 33
Multiple Sclerosis Variant 58
Multiple Sclerosis of Cord 33
Ms - [multiple Sclerosis] 33
Multiple Brain Sclerosis 33
Cerebrospinal Sclerosis 33
Insular Brain Sclerosis 33
Miliary Brain Sclerosis 33
Multiple Sclerosis 1 57
Sclérose En Plaques 33
Plaque Sclerosis 33

Characteristics:


Inheritance:

Multifactorial 57

OMIM®:

57 (Updated 24-Oct-2022)
Miscellaneous:
onset 20-55 years of age
women affected more than men (3:2)
association with the hla-drb1*1501-dqb1*0602 haplotype has been repeatedly demonstrated in high-risk (northern european) populations.


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:2377
OMIM® 57 126200
OMIM Phenotypic Series 57 PS126200
ICD9CM 34 340
MeSH 43 D009103
NCIt 49 C3243
SNOMED-CT 68 155023009
ICD10 31 G35
Orphanet 58 ORPHA228145
MedGen 40 C1868685
UMLS 71 C0026769

Summaries for Multiple Sclerosis

MedlinePlus Genetics: 42 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. The symptoms vary widely, and affected individuals can experience one or more effects of nervous system damage. Multiple sclerosis often causes sensory disturbances in the limbs, including a prickling or tingling sensation (paresthesia), numbness, pain, and itching. Some people experience Lhermitte sign, which is an electrical shock-like sensation that runs down the back and into the limbs. This sensation usually occurs when the head is bent forward. Problems with muscle control are common in people with multiple sclerosis. Affected individuals may have tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness or partial paralysis of the muscles of the limbs, difficulty walking, or poor bladder control. Multiple sclerosis is also associated with vision problems, such as blurred or double vision or partial or complete vision loss. Infections that cause fever can make the symptoms worse.There are several forms of multiple sclerosis: relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. The most common is the relapsing-remitting form, which affects approximately 80 percent of people with multiple sclerosis. Individuals with this form of the condition have periods during which they experience symptoms, called clinical attacks, followed by periods without any symptoms (remission). The triggers of clinical attacks and remissions are unknown. After about 10 years, relapsing-remitting MS usually develops into another form of the disorder called secondary progressive MS. In this form, there are no remissions, and symptoms of the condition continually worsen.Primary progressive MS is the next most common form, affecting approximately 10 to 20 percent of people with multiple sclerosis. This form is characterized by constant symptoms that worsen over time, with no clinical attacks or remissions. Primary progressive MS typically begins later than the other forms, around age 40.Progressive relapsing MS is a rare form of multiple sclerosis that initially appears like primary progressive MS, with constant symptoms. However, people with progressive relapsing MS also experience clinical attacks of more severe symptoms.

MalaCards based summary: Multiple Sclerosis, also known as ms, is related to pediatric multiple sclerosis and autoimmune hepatitis, and has symptoms including back pain, headache and hemiplegia. An important gene associated with Multiple Sclerosis is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Phosphorylation of CD3 and TCR zeta chains and Cell differentiation - expanded index. The drugs Acetaminophen and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are spasticity and diplopia

NINDS: 52 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye.  Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance.  These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis.  Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations.  Some may also experience pain.  Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked.  Depression is another common feature of MS.

MedlinePlus: 41 Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include: Visual disturbances Muscle weakness Trouble with coordination and balance Sensations such as numbness, prickling, or "pins and needles" Thinking and memory problems No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk. There is no specific test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

UniProtKB/Swiss-Prot: 73 A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

OMIM®: 57 Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system (CNS) with various degrees of axonal damage. MS affects mainly young adults with predominance for females. The disorder often leads to substantial disability (summary by Bomprezzi et al., 2003). (126200) (Updated 24-Oct-2022)

Disease Ontology: 11 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

Wikipedia: 75 Multiple sclerosis (MS), also known as encephalomyelitis disseminata, is the most common demyelinating... more...

Related Diseases for Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2020)
# Related Disease Score Top Affiliating Genes
1 pediatric multiple sclerosis 33.4 HLA-DRB1 HLA-DQB1
2 autoimmune hepatitis 31.5 PDCD1 HLA-DRB1 HLA-DQB1
3 nervous system disease 31.2 PDCD1 MIR96 MIR223 MIR20B MIR20A MIR18B
4 narcolepsy 1 31.1 HLA-DRB1 HLA-DQB1
5 central nervous system disease 31.1 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
6 psoriasis 31.1 MIR326 MIR20A MIR17 MIR142 HLA-DRB1
7 disease by infectious agent 31.1 MIR223 MIR20A MIR17 MIR142
8 cerebrovascular disease 31.0 MIR223 MIR17 MIR145 MIR142
9 immune deficiency disease 31.0 PDCD1 MIR223 MIR20A MIR17 MIR142 HLA-DQB1
10 brain cancer 30.9 MIR20A MIR17 MIR145 MIR142
11 severe cutaneous adverse reaction 30.8 PDCD1 HLA-DRB1 HLA-DQB1
12 autoimmune disease of central nervous system 30.8 MIR223 MIR142 HLA-DRB1
13 primary biliary cholangitis 30.7 PDCD1 MIR326 MIR223 MIR20A MIR17 MIR142
14 diabetes mellitus 30.7 PDCD1 NR1H3 MIR223 MIR20A MIR17 MIR145
15 leukemia, acute myeloid 30.7 PDCD1 MIR326 MIR223 MIR17 MIR145 MIR142
16 retinal vascular disease 30.6 MIR20B MIR20A MIR17
17 bone resorption disease 30.6 MIR223 MIR17 MIR142
18 microvascular complications of diabetes 5 30.6 MIR20B MIR20A MIR17
19 leukemia, chronic lymphocytic 30.5 PDCD1 MIR223 MIR20A MIR17 MIR145 MIR142
20 narcolepsy 2 30.4 HLA-DRB1 HLA-DQB1
21 endometriosis 30.4 MIR223 MIR20A MIR17 MIR145 MIR142
22 pityriasis rosea 30.3 HLA-DRB1 HLA-DQB1
23 skin disease 30.3 PDCD1 MIR223 MIR20A MIR17 MIR142 HLA-DRB1
24 t-cell acute lymphoblastic leukemia 30.3 MIR223 MIR20B MIR17 MIR142
25 gastrointestinal system disease 30.2 MIR223 MIR20A MIR17 MIR145 MIR142
26 hematologic cancer 30.2 MIR223 MIR20A MIR17 MIR145 MIR142
27 spinal disease 30.2 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
28 eye disease 30.1 MIR223 MIR20B MIR20A MIR17 MIR142
29 central nervous system cancer 30.1 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
30 lymphoma, non-hodgkin, familial 30.0 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
31 connective tissue disease 30.0 MIR96 MIR223 MIR20B MIR20A MIR18B MIR17
32 kidney cancer 29.9 MIR20B MIR20A MIR17 MIR145 MIR142
33 inherited metabolic disorder 29.9 MIR223 MIR20A MIR17 MIR145 MIR142
34 retinal disease 29.8 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
35 malignant astrocytoma 29.8 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
36 retinal cancer 29.7 MIR20A MIR17 MIR142
37 chromosomal disease 29.7 MIR223 MIR17 MIR142
38 lymphatic system disease 29.7 MIR223 MIR20B MIR20A MIR17 MIR145 MIR142
39 arteries, anomalies of 29.7 MIR223 MIR20A MIR17 MIR145 MIR142
40 carbohydrate metabolic disorder 29.7 MIR223 MIR20A MIR17 MIR145 MIR142
41 urinary system disease 29.6 MIR223 MIR20A MIR17 MIR145 MIR142
42 thoracic cancer 29.6 MIR223 MIR20A MIR17 MIR145 MIR142
43 gastrointestinal system cancer 29.6 MIR223 MIR20A MIR17 MIR145 MIR142
44 breast disease 29.6 MIR223 MIR20A MIR17 MIR145 MIR142
45 bladder disease 29.6 MIR96 MIR223 MIR17 MIR145 MIR142
46 relapsing-remitting multiple sclerosis 11.9
47 secondary progressive multiple sclerosis 11.8
48 primary progressive multiple sclerosis 11.8
49 marburg acute multiple sclerosis 11.7
50 balo concentric sclerosis 11.6

Comorbidity relations with Multiple Sclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis:



Diseases related to Multiple Sclerosis

Symptoms & Phenotypes for Multiple Sclerosis

Human phenotypes related to Multiple Sclerosis:

30 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 spasticity 30 HP:0001257
2 diplopia 30 HP:0000651
3 emotional lability 30 HP:0000712
4 muscle weakness 30 HP:0001324
5 paresthesia 30 HP:0003401
6 urinary incontinence 30 HP:0000020
7 urinary hesitancy 30 HP:0000019
8 incoordination 30 HP:0002311
9 cns demyelination 30 HP:0007305
10 depression 30 HP:0000716

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Neurologic Central Nervous System:
spasticity
emotional lability
depression
high intensity area in white matter on head mri
cognitive dysfunction
more
Genitourinary Bladder:
urinary incontinence
urinary hesitancy
incomplete bladder emptying

Laboratory Abnormalities:
increased csf immunoglobulin levels
oligoclonal bands in csf
myelin basic protein in csf

Head And Neck Eyes:
diplopia
vision loss, monocular

Neurologic Peripheral Nervous System:
incoordination
weakness
sensory loss
paresthesias

Clinical features from OMIM®:

126200 (Updated 24-Oct-2022)

UMLS symptoms related to Multiple Sclerosis:


back pain; headache; hemiplegia; muscle cramp; pain; sciatica; seizures; syncope; tremor; chronic pain; vertigo/dizziness; sleeplessness

Drugs & Therapeutics for Multiple Sclerosis

Drugs for Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
4
Phylloquinone Approved, Investigational Phase 4 572-96-3, 84-80-0 5280585 5284607
5
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
6
Cetirizine Approved Phase 4 83881-51-0 2678
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Tocopherol Approved, Investigational Phase 4 1406-66-2
9
Titanium dioxide Approved Phase 4 13463-67-7
10
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
13
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719 157920
14
Calcium carbonate Approved, Investigational Phase 4 471-34-1
15
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
16
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
17
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
18
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
19
Nabilone Approved, Investigational Phase 4 51022-71-0 39860 5284592
20
Montelukast Approved Phase 4 158966-92-8 5281040
21
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
22
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
23
Ofatumumab Approved Phase 4 679818-59-8
24
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
25
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
26
Topiramate Approved Phase 4 97240-79-4 5284627
27
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
28
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
29
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
30
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
31
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
32
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
33
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
34
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
35
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
36
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
37
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
38
Amitriptyline Approved Phase 4 50-48-6 2160
39
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
40
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
41
Testosterone enanthate Approved Phase 4 315-37-7 9416
42
Methyltestosterone Approved Phase 4 58-18-4 6010
43
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
44
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
45
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
46
Venlafaxine Approved Phase 4 99300-78-4, 93413-69-5 5656
47
Norepinephrine Approved Phase 4 51-41-2 439260
48
Simethicone Approved Phase 4 8050-81-5
49
Loperamide Approved Phase 4 53179-11-6 3955
50
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991

Interventional clinical trials:

(show top 50) (show all 2658)
# Name Status NCT ID Phase Drugs
1 Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
2 The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients Unknown status NCT01407211 Phase 4
3 Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients Unknown status NCT01417273 Phase 4 Drug: placebo
4 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
5 A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod) Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
6 Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
7 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Unknown status NCT03092544 Phase 4 dimethyl fumarate
8 Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses Unknown status NCT03021317 Phase 4 ACTHar
9 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
10 Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation Unknown status NCT04230174 Phase 4 11C-PBR28
11 Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY) Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
12 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
13 A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a Unknown status NCT03424733 Phase 4 Plegridy;Prednisone;Tylenol Pill
14 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
15 A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting Completed NCT01930708 Phase 4 dimethyl fumarate
16 Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis (MS) Completed NCT02307838 Phase 4
17 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
18 BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
19 A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®). Completed NCT02142205 Phase 4
20 Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) Completed NCT03091569 Phase 4
21 De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
22 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Completed NCT02255656 Phase 4 alemtuzumab GZ402673
23 Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®
24 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Completed NCT01395316 Phase 4 Alemtuzumab
25 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis Completed NCT01225289 Phase 4 Placebo
26 A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE) Completed NCT02125604 Phase 4 dimethyl fumarate
27 A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya® Completed NCT01705236 Phase 4 Fingolimod
28 A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France Completed NCT01420055 Phase 4 fingolimod
29 A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis. Completed NCT01498887 Phase 4 Fingolimod (FTY720)
30 A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
31 A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week Completed NCT02019550 Phase 4
32 Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM) Completed NCT02587065 Phase 4 peginterferon beta-1a
33 An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod) Completed NCT04792567 Phase 4 BAF312;Baseline disease modifying therapies (DMTs)
34 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
35 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
36 A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device Completed NCT01791244 Phase 4 Rebif®
37 Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b Completed NCT01842191 Phase 4
38 A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
39 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC) Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
40 A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
41 A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies Completed NCT00492466 Phase 4 Interferon-beta-1a;methylprednisolone
42 Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis Completed NCT00367484 Phase 4
43 The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®). Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif
44 A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex Completed NCT00206648 Phase 4 Betaferon/Betaseron
45 Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone Completed NCT00203021 Phase 4 Glatiramer acetate
46 Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720) Completed NCT02720107 Phase 4 fingolimod
47 Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®) Completed NCT00534261 Phase 4 Interferon beta-1a
48 A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy. Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
49 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study Completed NCT00871780 Phase 4 BG00002 (natalizumab)
50 A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function Completed NCT00315367 Phase 4 Donepezil HCI (drug)

Search NIH Clinical Center for Multiple Sclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Baclofen
CARBOXYMETHYLCELLULOSE CALCIUM
Cladribine
COBALAMIN CONCENTRATE
Cyclophosphamide
Daclizumab
Dantrolene
Dantrolene Sodium
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
Interferon beta-1a
interferon beta-1b
mecobalamin
Mitoxantrone
Mitoxantrone Hydrochloride
natalizumab
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Sclerosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Multiple Sclerosis:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem, bone marrow-derived cells for neurological disorders
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn, mesenchymal stem cells secreting NTF for neurodegenerative diseases
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna, autologous T-cell immunotherapy for multiple sclerosis
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374 22236384 21366911
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19603590 19127447
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis

Genetic tests related to Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 28
2 Multiple Sclerosis, Susceptibility to 1 28
3 Multiple Sclerosis, Susceptibility to 28 HLA-DQB1 HLA-DRB1 PDCD1

Anatomical Context for Multiple Sclerosis

Organs/tissues related to Multiple Sclerosis:

MalaCards : Spinal Cord, Brain, Bone Marrow, Monocytes, Eye, T Cells, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis:
# Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis

Articles related to Multiple Sclerosis:

(show top 50) (show all 32024)
# Title Authors PMID Year
1
Risk alleles for multiple sclerosis identified by a genomewide study. 53 62 57 5
17660530 2007
2
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. 53 62 57 5
15912506 2005
3
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. 53 62 57 5
10803840 2000
4
A mutated CCR5 gene may have favorable prognostic implications in MS. 53 57 5
12874407 2003
5
APOE epsilon4 and the cognitive genetics of multiple sclerosis. 53 62 57
20479360 2010
6
The role of the CD58 locus in multiple sclerosis. 53 62 57
19237575 2009
7
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. 53 62 57
18656179 2008
8
Cystatin C in cerebrospinal fluid and multiple sclerosis. 53 62 57
16900522 2007
9
Cleavage of cystatin C is not associated with multiple sclerosis. 53 62 57
17006926 2007
10
A second major histocompatibility complex susceptibility locus for multiple sclerosis. 53 62 57
17252545 2007
11
Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. 53 62 57
16437581 2006
12
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. 53 62 57
12533090 2003
13
A controlled trial of natalizumab for relapsing multiple sclerosis. 53 62 57
12510038 2003
14
Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. 53 62 57
11836653 2002
15
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. 53 62 57
11528386 2001
16
A point mutation in PTPRC is associated with the development of multiple sclerosis. 53 62 57
11101853 2000
17
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. 62 57
35073561 2022
18
Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. 62 5
27253448 2016
19
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. 62 57
23444327 2013
20
No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. 62 57
23483640 2013
21
Potassium channel KIR4.1 as an immune target in multiple sclerosis. 62 57
22784115 2012
22
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. 62 57
22095036 2012
23
Rare variants in the CYP27B1 gene are associated with multiple sclerosis. 62 57
22190362 2011
24
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. 62 57
21833088 2011
25
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. 62 57
21061396 2010
26
Upregulation of K2P5.1 potassium channels in multiple sclerosis. 62 57
20582984 2010
27
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. 62 57
20190274 2010
28
Silencing Nogo-A promotes functional recovery in demyelinating disease. 53 57
20437585 2010
29
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. 62 57
20428171 2010
30
A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. 62 57
19888296 2010
31
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. 62 57
20007504 2010
32
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. 62 57
20159113 2010
33
What role for genetics in the prediction of multiple sclerosis? 62 57
20186855 2010
34
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. 62 57
19293837 2009
35
Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. 53 57
19786693 2009
36
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. 62 57
19667218 2009
37
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. 62 57
19525953 2009
38
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. 62 57
19525955 2009
39
Risk alleles for multiple sclerosis in multiplex families. 62 57
19506219 2009
40
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. 62 57
19416878 2009
41
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. 62 57
19111528 2009
42
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. 62 57
19197344 2009
43
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. 62 57
19010793 2009
44
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. 62 57
19098025 2009
45
Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. 62 57
18953350 2008
46
Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. 62 57
19029521 2008
47
The immunogenetics of multiple sclerosis. 62 57
18461312 2008
48
Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. 62 57
18541802 2008
49
An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. 62 57
18087043 2007
50
Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. 62 57
17646631 2007

Variations for Multiple Sclerosis

ClinVar genetic disease variations for Multiple Sclerosis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NR1H3 NM_005693.4(NR1H3):c.1244G>A (p.Arg415Gln) SNV Pathogenic
226296 rs61731956 GRCh37: 11:47290147-47290147
GRCh38: 11:47268596-47268596
2 RNF217 NM_001286398.3(RNF217):c.1370G>A (p.Arg457His) SNV Risk Factor
1338812 GRCh37: 6:125397891-125397891
GRCh38: 6:125076745-125076745
3 DNAAF11 NM_012472.6(DNAAF11):c.1391C>T (p.Pro464Leu) SNV Risk Factor
260273 rs139131485 GRCh37: 8:133584564-133584564
GRCh38: 8:132572316-132572316
4 CCR5, CCR5AS NM_001394783.1(CCR5):c.554_585del (p.Ser185fs) DEL Risk Factor
8184 rs333 GRCh37: 3:46414944-46414975
GRCh38: 3:46373453-46373484
5 PDCD1 NM_005018.3(PDCD1):c.627+189G>C SNV Risk Factor
9251 rs11568821 GRCh37: 2:242793912-242793912
GRCh38: 2:241851760-241851760
6 HLA-DRB1 HLA-DRB1, DRB1*1501 VAR Risk Factor
29757 GRCh37:
GRCh38:

Copy number variations for Multiple Sclerosis from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19629 1 150852910 150853198 Copy number LCE3B Multiple sclerosis
2 82393 14 105506863 105509403 Copy number ADAM6 Multiple sclerosis
3 150742 20 13924145 15981841 Copy number MACROD2 Multiple sclerosis
4 224845 7 38265768 38282444 Copy number TARP Multiple sclerosis

Expression for Multiple Sclerosis

LifeMap Discovery
Genes differentially expressed in tissues of Multiple Sclerosis patients vs. healthy controls: 35 (show all 20)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 HBD hemoglobin subunit delta Blood + 4.09 0.000
2 LTF lactotransferrin Blood + 3.94 0.000
3 ALAS2 5'-aminolevulinate synthase 2 Blood + 3.75 0.000
4 BOD1L1 biorientation of chromosomes in cell division 1 like 1 Blood + 3.72 0.000
5 FBXO11 F-box protein 11 Spinal Cord + 3.70 0.005
6 MALAT1 metastasis associated lung adenocarcinoma transcript 1 Blood + 3.69 0.000
7 CPT1A carnitine palmitoyltransferase 1A Spinal Cord + 3.62 0.004
8 ZNF695 zinc finger protein 695 Spinal Cord - 3.58 0.001
9 WBP2NL WBP2 N-terminal like Spinal Cord - 3.43 0.015
10 CLEC4A C-type lectin domain family 4 member A Spinal Cord + 3.41 0.016
11 SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 Blood + 3.39 0.000
12 PUS7 pseudouridine synthase 7 Spinal Cord + 3.34 0.038
13 SLC2A10 solute carrier family 2 member 10 Spinal Cord + 3.33 0.006
14 EIF5A eukaryotic translation initiation factor 5A Blood - 3.30 0.000
15 CLC Charcot-Leyden crystal galectin Blood + 3.20 0.000
16 FAM118A family with sequence similarity 118 member A Spinal Cord - 3.20 0.007
17 HBM hemoglobin subunit mu Blood + 3.15 0.000
18 HINT3 histidine triad nucleotide binding protein 3 Blood - 3.10 0.000
19 CAB39L calcium binding protein 39 like Spinal Cord + 3.07 0.000
20 IGHD immunoglobulin heavy constant delta Blood + 3.05 0.000
Search GEO for disease gene expression data for Multiple Sclerosis.

Pathways for Multiple Sclerosis

Pathways related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.23 PDCD1 HLA-DRB1 HLA-DQB1
2
Show member pathways
11.15 MIR223 MIR20A MIR17 MIR145
3 10.75 MIR223 MIR20A MIR17 MIR145

GO Terms for Multiple Sclerosis

Cellular components related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.58 MIR96 MIR326 MIR223 MIR20B MIR20A MIR18B
2 extracellular vesicle GO:1903561 9.26 MIR422A MIR20B MIR20A MIR17

Biological processes related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.88 NR1H3 MIR223 MIR20A MIR17
2 humoral immune response GO:0006959 9.85 PDCD1 HLA-DRB1 HLA-DQB1
3 miRNA-mediated gene silencing GO:0035195 9.64 MIR96 MIR599 MIR422A MIR326 MIR223 MIR20B
4 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.46 MIR96 MIR20A MIR17 MIR145
5 immunoglobulin production involved in immunoglobulin-mediated immune response GO:0002381 9.43 HLA-DRB1 HLA-DQB1
6 negative regulation of vascular endothelial growth factor production GO:1904046 9.43 MIR20B MIR20A MIR17
7 negative regulation of inflammatory response GO:0050728 9.43 MIR142 MIR145 MIR20A MIR223 NR1H3
8 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.4 HLA-DRB1 HLA-DQB1
9 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.37 MIR20A MIR17
10 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.32 MIR20A MIR17

Molecular functions related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR96 MIR326 MIR223 MIR20B MIR20A MIR17
2 MHC class II receptor activity GO:0032395 9.33 HLA-DRB1 HLA-DQB1
3 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR96 MIR326 MIR223 MIR20B MIR20A MIR18B

Sources for Multiple Sclerosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....